SAN FRANCISCO, CA - October 31, 2001-NimbleGen Systems, Inc., a closely held genomics technology company, announced that Michael Treble, President and CEO of NimbleGen, will present at the Oxford Bioscience Partners and Ernst & Young's National Conference on Biotech Ventures at the What's New in Drug Discovery session, today at 10:30 a.m. at the Ritz Carlton, San Francisco, California. Mr. Treble will present an overview of the investment opportunity for its DNA array technology.

NimbleGen produces Custom High Density DNA Arrays and is developing DNA Array Systems that are based upon its proprietary Maskless Array Synthesizer (MAS) technology. The MAS technology permits the Company to develop and manufacture custom DNA arrays in less than four hours which have the consistency of traditionally manufactured arrays, allowing researches to do massively parallel analysis of gene expression in many different genomes. NimbleGen has the exclusive worldwide license to the MAS technology from WARF. The inventors of the technology from the University of Wisconsin include Dr. Fredrick Blattner, Dr. Michael Sussman, Dr. Franco Cerrina and Dr. Roland Green.

Wisconsin-based NimbleGen is developing and commercializing systems to acquire, analyze and manage complex genetic information using its Maskless Array Systems to empower users. The Company's system consists of high density, custom DNA arrays containing gene sequences on a chip, reagents for use with the DNA arrays and instruments to process custom DNA arrays and software to analyze and manage genetic information.